Summary
• Ensysce Biosciences’ stock rose 5% in after-hours trading, reaching $1.65.
• Positive FDA feedback on PF614 manufacturing may contribute to improved investor sentiment.
• Despite recent gains, the stock remains significantly below key moving averages and has a year-to-date decline of 74.7%.
Ensysce Biosciences, Inc. experienced a notable rise in after-hours trading, with shares climbing to $1.65 from a previous close of $1.57, reflecting a 5% increase. This uptick comes in a market setting that offers limited fresh news, although earlier developments indicate positive regulatory feedback.
Positive Regulatory Momentum
While today’s price movement lacks a direct recent catalyst, the company has previously received encouraging feedback from the FDA regarding its PF614 manufacturing approach. On November 20, 2025, Ensysce announced that the FDA provided written responses to its request for guidance, which could help advance the path to commercial production of PF614. This news, albeit older, reflects the potential for significant future growth and has likely contributed to the recent positive trading sentiment.
Market and Technical Overview
Ensysce’s stock exhibits a mixed performance profile. While the current after-hours price represents a modest rally, the company’s longer-term metrics are concerning. The stock remains significantly below its 20-day, 50-day, and 200-day simple moving averages, with deviations of -16.7%, -26.7%, and -38.3% respectively. The year-to-date performance is down 74.7%, revealing a persistent bearish trend. Despite the recent surge, the stock has struggled amidst consistent volatility, with a monthly volatility rating of 8.32 and a quarterly performance drawdown of 0.96%.
Trading volume in after-hours was low, at around 700 shares compared to the average volume of 57,430 over the past 10 days and 108,375 for the last three months. This discrepancy suggests that while there is some interest, the robust volume is lacking to support a sustained price rally.
Analyst Sentiment and Outlook
Ensysce currently holds a “Buy” rating from analysts, reflecting some confidence in the company’s operational direction. However, the significant discrepancies between actual and estimated earnings results demonstrate the challenges the company faces. Recently, the company reported an actual earnings loss of $1.29 per share against an estimate of $0.85, marking a surprise of over 51%. This large margin indicates the ongoing struggles within the company, reinforcing the need for solid execution moving forward.
Closing Thoughts
With shares reacting favorably amid prior positive regulatory developments, investors will continue to monitor how the stock’s price momentum is affected by trading activities as well as upcoming operational milestones. The company’s ability to translate regulatory feedback into commercial success will be crucial for its future performance metrics.
